XORTX Therapeutics
XRTX
6 hedge funds and large institutions have $324K invested in XORTX Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
689% more capital invested
Capital invested by funds: $41.1K → $324K (+$283K)
1.61% more ownership
Funds ownership: 0.17% → 1.78% (+1.6%)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$366K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$2.52K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.86K |
| 3 |
JP Morgan Chase
New York
|
-$1.21K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$138 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $299K | +$366K | +53,000 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $19.7K | -$1.86K | -270 | -7% |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.14K | +165 | +123% |
|
|
4
National Bank of Canada
Montreal,
Quebec, Canada
| $1.74K | -$2.52K | -365 | -53% |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $1.3K | – | – | – |
|
|
CA
6
Clearstead Advisors
Cleveland,
Ohio
| $313 | – | – | – |
|
|
7
JP Morgan Chase
New York
| – | -$1.21K | -51 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$138 | -17 | Closed |
|
XRTX Hedge Fund Activity: Q4 2024 in Review
6 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2024, worth a combined $324K — up 689% from $41.1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XRTX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $366K. The largest seller was National Bank of Canada, cutting an estimated $2.52K.
- 6 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2024, down from 7 in Q3 2024.
- Funds reported $324K of XORTX Therapeutics stock for Q4 2024, up 689% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q4 2024 and 2 closed out, a net change of -1 holder.
- The largest XORTX Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $366K added.
- The largest XORTX Therapeutics seller in Q4 2024 was National Bank of Canada, an estimated $2.52K sold.
Based on aggregated 13F filings for Q4 2024.